Product Program year 2022 Source: CMS Open Payments

Eysuvis

Drug Ocular

NDC 71571-333-83

Open in the dashboard

General payments

$2,373,779

24,418 payments

Research payments

$0

0 payments

Through program year 2022, $2,373,779 in general payments and $0 in research payments were reported against Eysuvis (Ocular).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2022 General $246,649 5,238
2021 General $1,683,708 18,947
2020 General $443,421 233

Breakdown

Who paid General payments · program years 2020–2022
  1. Kala Pharmaceuticals, Inc. $2,373,779 24,418 payments
Top recipients General payments · program year 2022
  1. Edward Holland Ophthalmology · Edgewood, KY $15,981 6% · 10 payments
  2. Victor Perez Quinones Cornea and External Diseases Specialist · Durham, NC $9,430 4% · 2 payments
  3. Marc Bloomenstein Optometrist · Scottsdale, AZ $7,115 3% · 13 payments
  4. Leslie O Dell Optometrist · New Freedom, PA $6,978 3% · 9 payments
  5. Preeya Gupta Ophthalmology · Raleigh, NC $6,181 3% · 5 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2022.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2022
  1. Ophthalmology $110,271 46% · 1,230 practitioners
  2. Optometrist $101,062 42% · 1,669 practitioners
  3. Cornea and External Diseases Specialist Ophthalmology $18,196 8% · 25 practitioners
  4. Optometrist, Corneal and Contact Management Optometrist $3,877 2% · 36 practitioners
  5. Ophthalmic Plastic and Reconstructive Surgery Ophthalmology $3,485 1% · 9 practitioners

The top 5 of 27 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2022
  1. California $30,156 12% · 339 recipients
  2. Pennsylvania $24,630 10% · 194 recipients
  3. Florida $20,919 8% · 218 recipients
  4. North Carolina $18,935 8% · 137 recipients
  5. Texas $16,589 7% · 264 recipients

The top 5 of 48 states; each share is of general payments naming this product in 2022 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

14,398

Prescriptions dispensed, refills included

Drug cost

$7,307,604

Paid at the pharmacy, in all

Prescribers

364

With 11 or more claims of it

Medicare Part D drugs matched to EYSUVIS, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Eysuvis Loteprednol Etabonate Same name 364 14,398 $7,307,604

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jeremy Cotliar Ophthalmology NY 1,179 $562,789 $23
Violeta Paronian Optometry CA 654 $323,840 $301
Harout Khanjian Optometry CA 461 $227,349 $333
Alan Mendelsohn Ophthalmology FL 370 $195,503 $177
Grant Lee Ophthalmology CA 323 $161,234 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
24,418 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record